Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $58.55 USD
Change Today -1.14 / -1.91%
Volume 426.5K
RDY On Other Exchanges
Symbol
Exchange
New York
Natl India
Mexico
Frankfurt
As of 8:04 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

doctor reddy's lab-adr (RDY) Snapshot

Open
$58.82
Previous Close
$59.69
Day High
$58.97
Day Low
$58.23
52 Week High
07/20/15 - $62.35
52 Week Low
08/6/14 - $44.04
Market Cap
10.0B
Average Volume 10 Days
232.1K
EPS TTM
--
Shares Outstanding
170.5M
EX-Date
07/8/15
P/E TM
--
Dividend
$0.31
Dividend Yield
0.53%
Current Stock Chart for DOCTOR REDDY'S LAB-ADR (RDY)

Related News

No related news articles were found.

doctor reddy's lab-adr (RDY) Related Businessweek News

No Related Businessweek News Found

doctor reddy's lab-adr (RDY) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to other companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the discovery, development, and commercialization of novel small molecule agents in therapeutic areas, such as anti-infective, metabolic disorders, and pain and inflammation. It also provides differentiated formulations for unmet medical needs; and a portfolio of in-licensed patented dermatology products As of March 31, 2015, this segment had 18 active products in proprietary products development pipeline that are in various stages of development. The company’s therapeutic categories primarily include gastro-intestinal, cardiovascular, pain management, oncology, dermatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; collaboration, license and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

20,373 Employees
Last Reported Date: 06/17/15
Founded in 1984

doctor reddy's lab-adr (RDY) Top Compensated Officers

Co-Chairman, Chief Executive Officer, Managin...
Total Annual Compensation: 6.3M
Chairman of the Board, Member of the Manageme...
Total Annual Compensation: 6.3M
Compensation as of Fiscal Year 2015.

doctor reddy's lab-adr (RDY) Key Developments

Dr. Reddy's Laboratories Ltd. Launches Dementia Drug in US

Dr Reddy's Laboratories Ltd. has launched Memantine hydrochloride tablets USP, 5mg and 10mg, which is indicated for the treatment of dementia, in the US. Memantine hydrochloride tablets USP is a therapeutic equivalent generic version of NAMENDA (memantine HCl) tablets approved by the FDA. Dr. Reddy's Memantine hydrochloride tablets USP, 5 mg is available in bottle count size of 60 and the Memantine hydrochloride tablets USP, 10 mg are available in bottle count sizes of 60 and 500.

Dr. Reddy's Laboratories Ltd. Launches Memantine Hydrochloride Tablets USP, 5 Mg and 10 Mg

Dr. Reddy's Laboratories Ltd. announced that it has launched Memantine Hydrochloride tablets USP, 5 mg and 10 mg., a therapeutic equivalent generic vesion of NAMENDA (memantine HCI tables in the US market approved by the United States Food & Administration.

Dr. Reddy's Laboratories Ltd. Proposes Final Dividend for the Financial Year 2014-2015, Payable on or After 7 August 2015

Dr. Reddy's Laboratories Ltd. announced that AGM will be held on July 31, 2015, to propose the dividend of INR 20 per share on equity share of INR 5 each as final dividend for the financial year 2014-2015. Dividend, if declared, at the Annual General Meeting, will be paid on or after 7 August 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDY:US $58.55 USD -1.14

RDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 735.30 INR +4.15
Cadila Healthcare Ltd 1,895 INR +15.25
Croda International PLC 2,997 GBp +50.00
Lonza Group AG SFr.140.40 CHF +4.10
Symrise AG €60.25 EUR +1.33
View Industry Companies
 

Industry Analysis

RDY

Industry Average

Valuation RDY Industry Range
Price/Earnings 28.0x
Price/Sales 4.2x
Price/Book 5.6x
Price/Cash Flow 28.0x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DOCTOR REDDY'S LAB-ADR, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.